KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) presented non-clinical data from ongoing research on ...
Research from the United States has demonstrated how PV technology can be used to kill cancer cells. Although still at an embryonic stage, the findings of the study and initial test results suggest ...
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical ...
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology ...
In an update for investors, Provectus Biopharmaceuticals (OTC:PVCT +2.5%) announces the current status of lead candidate PV-10 in GI cancer: Four-site Phase 1 study in patients with hepatic lesions ...
KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (PVCT) today announced that data from preclinical research by Moffitt Cancer Center (“Moffitt”) on PV-10 (rose ...
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment ...
— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS of 22.5 months; half of patients undergoing response follow-up — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback